Lymphoma & Myeloma 2016

 
 
 

Photo © 2016 HOK

Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies took place October 13 - 15 at the Waldorf-Astoria Hotel in New York City.

 

Combine flow and HTS for sensitive MRD detection in CLL, speaker says

Erilyn Riley Read Article
Published: 11/04/16

flow_cytometry_using_laser_beam_Credit_NIH_220_final.jpg
Flow cytometry using
laser beam
Photo courtesy of NIH

Combining 2 technologies—flow cytometry and high-throughput sequencing (HTS)—produces a very sensitive approach to detecting minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL), according to a speaker at Lymphoma & Myeloma 2016. The approach is both reproducible and widely accessible, added the speaker, Peter Hillmen, MB ChB, PhD, of St James’s University Hospital in Leeds, UK. [Read Article]

Rethinking testing in multiple myeloma

Erilyn Riley Read Article
Published: 10/31/16

plasma_cells_malignant_240.jpg
Malignant plasma cells

As the number of therapeutic options for multiple myeloma (MM) increases, so too does the need to reassess prognostic markers for the disease, according to a speaker at Lymphoma & Myeloma 2016. “A good prognosticator for one patient may have little meaning for another patient,” said Scott Ely, MD, of Weill Cornell Medicine in New York, New York. “It’s really important before doing any testing to ask, ‘Will the result of this test affect patient care?’” [Read Article]

Genetic screening for CLL premature, speaker says

Erilyn Riley Read Article
Published: 10/27/16

genome_testing_credit_National_Institute_of_General_Medical_Sciences-200.jpg
Genome testing
Photo courtesy of the
National Institute
of General Medical Science

Research has shown that family history is a strong risk factor for developing chronic lymphocytic leukemia (CLL). First-degree relatives have an 8.5-fold risk of getting CLL and an increased risk of other lymphoproliferative disorders, according to a study published in 2009. However, despite the strong evidence of a genetic contribution, one expert believes it’s premature to bring genetic testing into the clinic for screening in CLL. [Read Article]

No longer a hand-me-down approach to WM

Erilyn Riley Read Article
Published: 10/25/16

treon_steven_MD_PhD_Credit_DFCI_220.jpg
Steven Treon, MD, PhD
Photo courtesy of DFCI

Whole-genome sequencing has changed the entire approach to drug development for Waldenström’s macroglobulinemia (WM), according to a speaker at Lymphoma & Myeloma 2016. The strategy has changed from a hand-me-down one, relying on drugs developed first for other diseases, to a rational plan designed specifically to treat WM patients. “We would wait for our colleagues in the myeloma world or lymphoma world, CLL world . . . [Read Article]

Speaker says use the best regimen ASAP in MM

Erilyn Riley Read Article
Published: 10/22/16

multiple_myeloma_240.jpg
Multiple myeloma cells

It’s important to use the best possible regimen as soon as possible when treating patients with multiple myeloma (MM), according to a speaker at Lymphoma & Myeloma 2016. Antonio Palumbo, MD, of the University of Torino in Italy, explained that the urgency, from a biological point of view, is because myeloma accumulates genetic mutations that change the disease in a “dramatic way.” [Read Article]

Doc provides perspective on CAR T-cell therapy in CLL

Erilyn Riley Read Article
Published: 10/19/16

CTL019_Penn_Medicine_230.jpg
The CAR T-cell therapy CTL019
Photo from Penn Medicine

Trial data on the use of chimeric antigen receptor (CAR) T cells in chronic lymphocytic leukemia (CLL) are maturing, and a speaker at Lymphoma & Myeloma 2016 provided some perspective on the therapy as it now stands. Stephen J. Schuster, MD, of the University of Pennsylvania in Philadelphia, noted that some CLL patients treated with CAR T cells remain in complete remission (CR) for more than 5 years. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}